Jacobs Levy Equity Management
INBX icon

Jacobs Levy Equity Management’s Inhibrx INBX Stock Holding History

Jacobs Levy Equity Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$762K Buy
11,329
+1,188
+12% +$88.1K ﹤0.01% 759
2025
Q4 		$801K Sell
10,141
-3,578
-26% -$244K ﹤0.01% 722
2025
Q3 		$462K Buy
+13,719
New +$338K ﹤0.01% 830
2024
Q4 		– Sell
-20,469
Closed -$321K – 993
2024
Q3 		$321K Buy
+20,469
New +$288K ﹤0.01% 877

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jacobs Levy Equity Management's INBX Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Inhibrx (INBX) stake by 12% in Q1 2026, buying an estimated $88.1K and bringing the position to 11,329 shares worth $762K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Jacobs Levy Equity Management first reported a position in INBX in Q3 2024 and has held it in 4 quarters since. The position peaked at $801K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Jacobs Levy Equity Management held 11,329 shares of Inhibrx worth $762K as of Q1 2026.
  • Jacobs Levy Equity Management bought 1,188 Inhibrx shares in Q1 2026, an estimated $88.1K.
  • Inhibrx made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #759 holding.
  • Jacobs Levy Equity Management first reported a position in Inhibrx in Q3 2024 and has held it in 4 quarters since.
  • Jacobs Levy Equity Management's Inhibrx position peaked at $801K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.